

Special Issue

Therapeutic Applications of Micro-RNA in Cancer Management

Message from the Guest Editor

MiRNAs are small non-coding RNA sequences with a length of about 20 nucleotides that regulate gene expression. Their deregulation is associated with cancer, and they even act as oncogenes or tumor suppressor genes, playing an important role in tumor biology. In this sense, restoration of miRNA expression and inhibition of overexpressed miRNAs normalizes their function by reversing tumor cell phenotypes. Therefore, the idea of converting miRNAs into therapeutic agents is gaining relevance in this research field, through the use of synthetic molecules, nanoparticles, vesicles, quatsomes, etc., as vehicles for miRNAs to inhibit proliferation, cancer cell invasion, promote apoptosis, inhibit metastasis and increase sensitivity to treatments. This research is laying the groundwork for the application of miRNAs in cancer treatment. The journal *Pharmaceuticals* invites both reviews and original articles that shed light on advances in the therapeutic uses of miRNAs for cancer treatment. The collection of manuscripts will be published as a Special Issue of the journal.

Guest Editor

Dr. Alma D. Campos-Parra
Instituto de Salud Pública, Universidad Veracruzana (UV), Xalapa,
México

Deadline for manuscript submissions

closed (27 March 2026)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/207689

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)